Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

JNJ Johnson and Johnson

157,47

3,56 (2,31%)

17 Abr 2025 - Fechado

Atrasado em 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

02/25/2025

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Gerardo Ibarra-Munoz, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Robert J. Decker

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Mar 2025 até Abr 2025

Click aqui para mais gráficos Johnson and Johnson.

Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Abr 2024 até Abr 2025

Click aqui para mais gráficos Johnson and Johnson.

Notícias Johnson and Johnson

Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
Quarta, 16 de Abril de 2025 (3 dias atrás) • Business Wire

J&J aprova pagamento de dividendos para junho no valor estimado em R$ 0,3370 por BDR
Quarta, 16 de Abril de 2025 (4 dias atrás) • ADVFN News

Johnson & Johnson surpreende no 1º trimestre e revisa metas para 2025
Terça, 15 de Abril de 2025 (5 dias atrás) • ADVFN News

NYSE Content Advisory: Pre-Market update + Bank of America beats earnings estimates
Terça, 15 de Abril de 2025 (5 dias atrás) • PR Newswire (Canada)

Form 8-K - Current report
Terça, 15 de Abril de 2025 (5 dias atrás) • Edgar (US Regulatory)

Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%
Terça, 15 de Abril de 2025 (5 dias atrás) • Business Wire

Johnson & Johnson Reports Q1 2025 Results
Terça, 15 de Abril de 2025 (5 dias atrás) • Business Wire

Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill
Quinta, 10 de Abril de 2025 (1 semana atrás) • PR Newswire (US)

Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)
Terça, 8 de Abril de 2025 (2 semanas atrás) • PR Newswire (US)

Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference
Segunda, 7 de Abril de 2025 (2 semanas atrás) • Business Wire

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis
Sexta, 4 de Abril de 2025 (2 semanas atrás) • PR Newswire (US)

Form 8-K - Current report
Quinta, 3 de Abril de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Mais Notícias de Johnson and Johnson

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições